Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 1 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2025 Filed Apr 8, 2026 01:50 UTC |
Bardin StephenChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 67,728 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001942596-26-000002 · form4-04072026_090411.xml · derivative · entry 1 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,728 Underlying: Common Stock · 67,728 shares Expires 2036-04-04 F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision. Read SEC document |
| April 05, 2025 Filed Apr 8, 2026 01:50 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 83,358 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001576244-26-000002 · form4-04072026_090407.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,358 Underlying: Common Stock · 83,358 shares Expires 2036-04-04 F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision. Read SEC document |
| April 05, 2025 Filed Apr 8, 2026 01:50 UTC |
Stauderman Kenneth A.Chief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 65,124 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001969388-26-000002 · form4-04072026_090404.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,124 Underlying: Common Stock · 65,124 shares Expires 2036-04-04 F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 00:51 UTC |
Glicklich AlanDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001415889-25-001595 · form4-01172025_120159.xml · derivative · entry 1 Glicklich Alan · CIK 0001823197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-14 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 7, 2024 00:12 UTC |
Middleton Fred ADirector · 10% owner
|
PurchaseCommon Stock | 4,800 | $2.65 | $12,720.00 |
DisclosureSEC source: 0001415889-24-028563 · form4-12072024_121223.xml · nonDerivative · entry 1 MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,514 Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 17:25 UTC |
Leheny A. RachelDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 20,000 | $3.75 | $75,000.00 |
DisclosureSEC source: 0001415889-24-025880 · form4-11012024_051148.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,926 Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 17:22 UTC |
WILSON ROBERT NDirector
|
PurchaseCommon Stock | 53,333 | $3.75 | $199,998.75 |
DisclosureSEC source: 0001415889-24-025876 · form4-11012024_051102.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,529 Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 17:24 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
PurchaseCommon Stock | 53,333 | $3.75 | $199,998.75 |
DisclosureSEC source: 0001415889-24-025878 · form4-11012024_051115.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,706 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 15:08 UTC |
Sanderling Ventures Management VI10% owner
Sanderling Venture Partners VI LP10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
PurchaseCommon Stock | 877 | $3.75 | $3,288.75 |
DisclosureSEC source: 0001415889-24-026103 · form4-11052024_081117.xml · nonDerivative · entry 2 Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 22,479 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 15:08 UTC |
Sanderling Ventures Management VI10% owner
Sanderling Venture Partners VI LP10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
PurchaseCommon Stock | 86,867 | $3.75 | $325,751.25 |
DisclosureSEC source: 0001415889-24-026103 · form4-11052024_081117.xml · nonDerivative · entry 1 Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,300 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 20:04 UTC |
Middleton Fred ADirector · 10% owner
|
PurchaseCommon Stock | 877 | $3.75 | $3,288.75 |
DisclosureSEC source: 0001415889-24-026102 · form4-11052024_081149.xml · nonDerivative · entry 3 MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 22,479 F2 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 20:04 UTC |
Middleton Fred ADirector · 10% owner
|
PurchaseCommon Stock | 86,867 | $3.75 | $325,751.25 |
DisclosureSEC source: 0001415889-24-026102 · form4-11052024_081149.xml · nonDerivative · entry 2 MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 814,300 F1 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI Co-Investment Fund, LP ("SVP VI Co-Investment, LP", together with Sanderling Venture Partners VI, LP., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Securities"). The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 20:04 UTC |
Middleton Fred ADirector · 10% owner
|
PurchaseCommon Stock | 20,000 | $3.75 | $75,000.00 |
DisclosureSEC source: 0001415889-24-026102 · form4-11052024_081149.xml · nonDerivative · entry 1 MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,714 Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 21:00 UTC |
Dunn Michael J.President and COO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,761 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001415889-24-023226 · form4-09112024_050902.xml · derivative · entry 2 Dunn Michael J. · CIK 0001968792 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,761 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Received in exchange for a stock option to acquire 408,402 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer (formerly known as Graybug Vision, Inc.) and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 21:00 UTC |
Dunn Michael J.President and COO
|
Exercise / conversionCommon Stock | 11,761 | $1.39 | $16,347.79 |
DisclosureSEC source: 0001415889-24-023226 · form4-09112024_050902.xml · nonDerivative · entry 1 Dunn Michael J. · CIK 0001968792 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 23:44 UTC |
Leheny A. RachelDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 1,000 | $4.19 | $4,189.80 |
DisclosureSEC source: 0001415889-24-022361 · form4-08272024_110843.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,926 F1 · price: The weighted average purchase price for the transaction reported was $4.1898, and the range of prices were between $4.20 and $4.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:09 UTC |
Hebbar SudarshanChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022501 · form4-08282024_110856.xml · derivative · entry 1 Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:11 UTC |
Dunn Michael J.President and COO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022504 · form4-08282024_110824.xml · derivative · entry 1 Dunn Michael J. · CIK 0001968792 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:07 UTC |
Leheny A. RachelDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022500 · form4-08282024_110856.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:12 UTC |
Middleton Fred ADirector · 10% owner
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022506 · form4-08282024_110840.xml · derivative · entry 1 MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:12 UTC |
WILSON ROBERT NDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022505 · form4-08282024_110857.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:14 UTC |
BJERKHOLT ERICDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022508 · form4-08282024_110809.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:14 UTC |
Guerard FredericDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022509 · form4-08282024_110854.xml · derivative · entry 1 Guerard Frederic · CIK 0001825009 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:13 UTC |
Shaw AllanDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022507 · form4-08282024_110830.xml · derivative · entry 1 Shaw Allan · CIK 0001626850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:10 UTC |
Stauderman Kenneth A.Chief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022503 · form4-08282024_110845.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:10 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022502 · form4-08282024_110858.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 21:57 UTC |
WILSON ROBERT NDirector
|
PurchaseCommon Stock | 54,000 | $3.72 | $200,826.00 |
DisclosureSEC source: 0001415889-24-022242 · form4-08262024_090826.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,196 F1 · price: The weighted average purchase price for the transaction reported was $3.719, and the range of prices were between $3.50 and $3.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 22:00 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
PurchaseCommon Stock | 3,000 | $3.57 | $10,710.00 |
DisclosureSEC source: 0001415889-24-022243 · form4-08262024_090856.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 13,223 Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 22:00 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
PurchaseCommon Stock | 2,000 | $3.58 | $7,157.00 |
DisclosureSEC source: 0001415889-24-022243 · form4-08262024_090856.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 46,894 Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 22:02 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
PurchaseCommon Stock | 5,000 | $4.04 | $20,200.00 |
DisclosureSEC source: 0001415889-24-022058 · form4-08222024_100832.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 44,894 Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:50 UTC |
WILSON ROBERT NDirector
|
PurchaseCommon Stock | 51,278 | $3.52 | $180,498.56 |
DisclosureSEC source: 0001415889-24-018934 · form4-07022024_080711.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,196 F1 · price: The weighted average purchase price for the transaction reported was $3.52, and the range of prices were between $3.2997 and $3.7935. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 22:52 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
PurchaseCommon Stock | 5,000 | $3.22 | $16,100.00 |
DisclosureSEC source: 0001415889-24-018496 · form4-06282024_100627.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 10,223 Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 19:12 UTC |
WILSON ROBERT NDirector
|
PurchaseCommon Stock | 8,443 | $3.23 | $27,304.66 |
DisclosureSEC source: 0001415889-24-018567 · form4-07012024_070708.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,918 F1 · price: The weighted average purchase price for the transaction reported was $3.234, and the range of prices were between $3.17 and $3.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 17, 2024 Filed May 20, 2024 19:47 UTC |
Geffken Daniel E.Interim CFO
|
GrantWarrant · Derivative | 10,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001415889-24-013834 · form4-05202024_110554.xml · derivative · entry 1 Geffken Daniel E. · CIK 0001314756 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By SG Dan Equity Holdings, LLC Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-16 F1 · derivative.exercise_date: Beginning on May 17, 2024, the shares subject to the warrant shall vest and be exercisable in a series of twelve (12) successive equal monthly installments. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 00:33 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
PurchaseCommon Stock | 3,254 | $3.90 | $12,690.60 |
DisclosureSEC source: 0001415889-24-009884 · form4-04032024_120452.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 39,894 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 00:33 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
PurchaseCommon Stock | 746 | $3.90 | $2,909.40 |
DisclosureSEC source: 0001415889-24-009884 · form4-04032024_120452.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 36,640 Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:35 UTC |
Hebbar SudarshanChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011344 · form4-04232024_010443.xml · derivative · entry 1 Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:40 UTC |
Dunn Michael J.President and COO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011349 · form4-04232024_010442.xml · derivative · entry 1 Dunn Michael J. · CIK 0001968792 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:33 UTC |
Leheny A. RachelDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011343 · form4-04232024_010439.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:46 UTC |
Middleton Fred ADirector · 10% owner
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011351 · form4-04232024_010401.xml · derivative · entry 1 MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:43 UTC |
WILSON ROBERT NDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011350 · form4-04232024_010454.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:51 UTC |
BJERKHOLT ERICDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011353 · form4-04232024_010410.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:53 UTC |
Guerard FredericDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011354 · form4-04232024_010415.xml · derivative · entry 1 Guerard Frederic · CIK 0001825009 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:49 UTC |
Shaw AllanDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011352 · form4-04232024_010404.xml · derivative · entry 1 Shaw Allan · CIK 0001626850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:39 UTC |
Stauderman Kenneth A.Chief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011348 · form4-04232024_010428.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:37 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011346 · form4-04232024_010420.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 22:34 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
GrantWarrant · Derivative | 45,543 | $0.13 Strike: $7.15 | $5,692.88 |
DisclosureSEC source: 0001415889-24-002832 · form4-02062024_100209.xml · derivative · entry 9 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,543 Underlying: Common Stock · 45,543 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F4 · derivative.exercise_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F4 · derivative.expiration_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 22:34 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
GrantWarrant · Derivative | 45,543 | $0.13 Strike: $5.36 | $5,692.88 |
DisclosureSEC source: 0001415889-24-002832 · form4-02062024_100209.xml · derivative · entry 8 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,543 Underlying: Common Stock · 45,543 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 22:34 UTC |
Roberts Eric WDirector · CHIEF BUSINESS OFFICER · 10% owner
|
GrantCommon Stock | 91,086 | $4.27 | $388,618.42 |
DisclosureSEC source: 0001415889-24-002832 · form4-02062024_100209.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,373 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
PurchaseWarrant · Derivative | 14,372 | $0.13 Strike: $7.15 | $1,796.50 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 21 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 14,372 Underlying: Common Stock · 14,372 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.